NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

NCT05704829 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

402

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Early Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Standard-of-Care

Sponsor

West German Study Group

Collaborators

[object Object]